Skip to main content
. Author manuscript; available in PMC: 2010 Jul 1.
Published in final edited form as: J Altern Complement Med. 2009 Jul;15(7):745–753. doi: 10.1089/acm.2008.0589

Table 1. Baseline characteristics of study participants.

Characteristic Active acupuncture (n = 11) Sham acupuncture (n = 10)
Demographics
 Age ± SD 50.8 ± 10.6 50 ± 9.9
 Race
 White 11 (52.4%) 9 (42.9%)
 Black 0 (0%) 1 (4.8%)
ECOG performance status
 0 3 0
 1 8 7
New diagnosis 4 (19%) 5 (23.8%)
 Stage
 I 1 3
 II 2 0
 III 0 2
 IV 1 0
 Unknown 0 1
Recurrent disease 7 (33.3%) 5 (23.8%)
No. (%) of patients on specific drug treatment
 Carboplatin/paclitaxel 6 (28.6%) 5 (23.8%)
 Gemcitabine 3 (14.3%) 3 (14.3%)
 Topotecan 1 (4.8%) 2 (9.5%)
 Vinorelbine 1 (4.8%) 0 (0%)
Drug doses/course of chemotherapy, mg
 Carboplatin, mean ± SD 527.8 ± 120 632.2 ± 49.9
 Paclitaxel, mean ± SD 257.3 ± 81.4 280 ± 24.3
 Gemcitabine, mean ± SD 1809.5 ± 886 1873.3 ± 534.9
 Topotecan, mean ± SD 6.3 9.2 ± 3.6
 Vinorelbine, mean 67
 Dexamethasone, mean ± SD 13.7 ± 4.8 16 ± 12.6

SD, standard deviation; ECOG, Eastern Cooperative Oncology Group.